Drug Profile
Research programme: Parkinson's disease therapeutics - MRC Technology/Yabao Pharmaceutical Group
Alternative Names: SY 006Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator MRC Technology
- Developer LifeArc; Yabao Pharmaceutical Group
- Class Antiparkinsonians
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Parkinson's-disease in China
- 28 Dec 2018 No recent reports of development identified for research development in Parkinson's-disease in United Kingdom
- 15 Jun 2017 MRC Technology is now called LifeArc